


•  
•  
•  
•  
•  
**QUANTITATIVE LC-MS/MS**  
**Analysis of proteins and peptides**

Karolina Krasinska






# Overview

- Introduction: Quantitative approach to protein and peptide analysis
- Background: Instrumentation, workflow
- Assay development: Step by step
- Quantitative LC-MS/MS assay: method, results
- Common issues:
  - Matrix effect
  - Internal standard (IS)
  - Method validation
  - Analyte stability



# Absolute quantitation - targeted analysis

- Quantitation on peptide level



- Know what you are going to quantify:
  - well characterized protein
  - protein ID via LC-IT-MS/MS
  - in silico* digest based on theoretical AA sequence




# Sample

- Protein – unlimited size (gel, solution, biological matrix)
- Peptides – ideally 6-12 aa (up to 30-40 aa); may be phosphorylated
- Biological matrices:
  - plasma, serum, erythrocytes
  - cerebrospinal fluid (CSF)
  - urine
  - bile
  - cell culture media
  - plant and animal tissues (e.g. leaf, brain, liver)





# Analysis and data processing overview


## A) Analysis workflow



X  
+  
IS




## B) Data processing







# Triple quadrupole analyzer





# Advantages of SRM scanning mode

- MS/MS provides higher sensitivity and selectivity, enabling
  - Less extensive sample preparation
  - Greater sensitivity via increased selectivity
  - Use of shorter HPLC columns
  - Use of shorter run times and higher sample throughput
- Translates into time and effort savings, plus a more sensitive method





# Before we start – checklist

## Questions:

- What is the protein of interest? (MW, sequence, PTMs)
- Number of peptides included in the assay?
- Sample types? (matrices)
- Desired/required LLOQ and calibration range?
- Standards availability? (purified protein, peptides and labeled peptides)
- Purpose of developing the assay? (preliminary studies, confirmation of findings from different methods, publication)
- Available funding and timelines?



# Peptide selection rules

Main rules:

- 6-12 AA optimal (up to 30-40aa)
- No chemically reactive residues (Trp, Met, Cys)
- No ragged ends (2xR; RK; 2xK)
- No potential PTM
- unique sequence

Also consider:

- Preferably containing P (dominant cleavages)
- If MS/MS data already available than look for peptides giving high intensity fragment ions of  $m/z$  higher than precursor ion (noise reduction)
- R in P proximity (potential missed tryptic cleavage)
- Select multiple peptides for each protein whenever possible



# Protein X - fragment

Digest Table

| #  | Pos     | Mass  | pl | Peptide                      |
|----|---------|-------|----|------------------------------|
| 1  | 1213.50 | 9.50  |    | MAAVAALQLGLR                 |
| 2  | 543.62  | 9.79  |    | AAGLGR                       |
| 3  | 828.93  | 9.79  |    | APASAAWR                     |
| 4  | 473.57  | 9.47  |    | SVLR                         |
| 5  | 1464.69 | 12.30 |    | VSPRPGVAWRPSR                |
| 6  | 1082.15 | 5.99  |    | CGSSAAEASATK                 |
| 7  | 3203.69 | 4.03  |    | AEDDSFLQWVLLIIPVTAFGLGTWQVQR |
| 8  | 174.20  | 9.75  |    | R                            |
| 9  | 146.19  | 8.75  |    | K                            |
| 10 | 332.40  | 8.75  |    | WK                           |
| 11 | 1157.33 | 4.53  |    | LNLIAELESR                   |
| 12 | 1719.07 | 4.14  |    | VLAEPVPLPADPMELK             |
| 13 | 1018.18 | 8.59  |    | NLEYRPVK                     |
| 14 | 273.34  | 9.72  |    | VR                           |
| 15 | 792.86  | 6.73  |    | GCFDHSK                      |
| 16 | 939.16  | 6.10  |    | ELYMMPR                      |

Digest Table

| #  | Pos     | Mass | pl | Peptide                     |
|----|---------|------|----|-----------------------------|
| 17 | 816.97  | 5.50 |    | TMVDPVR                     |
| 18 | 374.40  | 6.10 |    | EAR                         |
| 19 | 2654.93 | 5.32 |    | EGGLISSSTQSGAYVVTPFHCTDLGK  |
| 20 | 146.19  | 8.75 |    | K                           |
| 21 | 714.78  | 5.97 |    | VNPETR                      |
| 22 | 274.32  | 8.75 |    | QK                          |
| 23 | 1515.74 | 4.14 |    | GQIEGEVDLIGMVR              |
| 24 | 618.69  | 6.00 |    | LTETR                       |
| 25 | 1326.43 | 4.53 |    | QPFPENNPER                  |
| 26 | 911.98  | 8.76 |    | NHWHYR                      |
| 27 | 804.92  | 4.37 |    | DLEAMAR                     |
| 28 | 2744.06 | 4.37 |    | ITGAEPIFIDANFQSTVPGGPIGGQTR |
| 29 | 487.60  | 9.72 |    | VTLR                        |
| 30 | 2791.16 | 6.75 |    | NEHLQYIVTWYGLSAATSYLWFK     |
| 31 | 146.19  | 8.75 |    | K                           |
| 32 | 434.54  | 9.75 |    | FLR                         |
| 33 | 429.47  | 5.52 |    | GTPGV                       |



# Protein X - fragment

Digest Table

| #  | Pos     | Mass  | pl | Peptide                      |
|----|---------|-------|----|------------------------------|
| 1  | 1213.50 | 9.50  |    | MAAVAALQLGLR                 |
| 2  | 543.62  | 9.79  |    | AAGLGR                       |
| 3  | 828.93  | 9.79  |    | APASAAWR                     |
| 4  | 473.57  | 9.47  |    | SVLR                         |
| 5  | 1464.69 | 12.30 |    | VSPRPGVAWRPSR                |
| 6  | 1082.15 | 5.99  |    | CGSSAAEASATK                 |
| 7  | 3203.69 | 4.03  |    | AEDDSFLQWVLLIIPVTAFGLGTWQVQR |
| 8  | 174.20  | 9.75  |    | R                            |
| 9  | 146.19  | 8.75  |    | K                            |
| 10 | 332.40  | 8.75  |    | WK                           |
| 11 | 1157.33 | 4.53  |    | LNLIAELESR                   |
| 12 | 1719.07 | 4.14  |    | VLAEPVPLPADPMELK             |
| 13 | 1018.18 | 8.59  |    | NLEYRPVK                     |
| 14 | 273.34  | 9.72  |    | VR                           |
| 15 | 792.86  | 6.73  |    | GCFDHSK                      |
| 16 | 939.16  | 6.10  |    | ELYMMPR                      |

Digest Table

| #  | Pos     | Mass | pl | Peptide                     |
|----|---------|------|----|-----------------------------|
| 17 | 816.97  | 5.50 |    | TMVDPVR                     |
| 18 | 374.40  | 6.10 |    | EAR                         |
| 19 | 2654.93 | 5.32 |    | EGGLISSSTQSGAYVVTPFHCTDLGK  |
| 20 | 146.19  | 8.75 |    | K                           |
| 21 | 714.78  | 5.97 |    | VNPETR                      |
| 22 | 274.32  | 8.75 |    | QK                          |
| 23 | 1515.74 | 4.14 |    | GQIEGEVDLIGMVR              |
| 24 | 618.69  | 6.00 |    | LTETR                       |
| 25 | 1326.43 | 4.53 |    | QPFPENNPER                  |
| 26 | 911.98  | 8.76 |    | NHWHYR                      |
| 27 | 804.92  | 4.37 |    | DLEAMAR                     |
| 28 | 2744.06 | 4.37 |    | ITGAEPIFIDANFQSTVPGGPIGGQTR |
| 29 | 487.60  | 9.72 |    | VTLR                        |
| 30 | 2791.16 | 6.75 |    | NEHLQYIVTWYGLSAATSYLWFK     |
| 31 | 146.19  | 8.75 |    | K                           |
| 32 | 434.54  | 9.75 |    | FLR                         |
| 33 | 429.47  | 5.52 |    | GTPGV                       |



# Protein X - fragment

Digest Table

| #  | Pos     | Mass  | pl | Peptide                      |
|----|---------|-------|----|------------------------------|
| 1  | 1213.50 | 9.50  |    | MAAVAALQLGLR                 |
| 2  | 543.62  | 9.79  |    | AAGLGR                       |
| 3  | 828.93  | 9.79  |    | APASAAWR                     |
| 4  | 473.57  | 9.47  |    | SVLR                         |
| 5  | 1464.69 | 12.30 |    | VSPRPGVAWRPSR                |
| 6  | 1082.15 | 5.99  |    | CGSSAAEASATK                 |
| 7  | 3203.69 | 4.03  |    | AEDDSFLQWVLLIIPVTAFGLGTWQVQR |
| 8  | 174.20  | 9.75  |    | R                            |
| 9  | 146.19  | 8.75  |    | K                            |
| 10 | 332.40  | 8.75  |    | WK                           |
| 11 | 1157.33 | 4.53  |    | LNLIAELESR                   |
| 12 | 1719.07 | 4.14  |    | VLAEPVPLPADPMELK             |
| 13 | 1018.18 | 8.59  |    | NLEYRPVK                     |
| 14 | 273.34  | 9.72  |    | VR                           |
| 15 | 792.86  | 6.73  |    | GCFDHSK                      |
| 16 | 939.16  | 6.10  |    | ELYMMPR                      |

Digest Table

| #  | Pos     | Mass | pl | Peptide                     |
|----|---------|------|----|-----------------------------|
| 17 | 816.97  | 5.50 |    | TMVDPVR                     |
| 18 | 374.40  | 6.10 |    | EAR                         |
| 19 | 2654.93 | 5.32 |    | EGGLISSSTQSGAYVVTPFHCTDLGK  |
| 20 | 146.19  | 8.75 |    | K                           |
| 21 | 714.78  | 5.97 |    | VNPETR                      |
| 22 | 274.32  | 8.75 |    | QK                          |
| 23 | 1515.74 | 4.14 |    | GQIEGEVDLIGMVR              |
| 24 | 618.69  | 6.00 |    | LTETR                       |
| 25 | 1326.43 | 4.53 |    | QPFVPENNPER                 |
| 26 | 911.98  | 8.76 |    | NHWHYR                      |
| 27 | 804.92  | 4.37 |    | DLEAMAR                     |
| 28 | 2744.06 | 4.37 |    | ITGAEPIFIDANFQSTVPGGPIGGQTR |
| 29 | 487.60  | 9.72 |    | VTLR                        |
| 30 | 2791.16 | 6.75 |    | NEHLQYIVTWYGLSAATSYLWFK     |
| 31 | 146.19  | 8.75 |    | K                           |
| 32 | 434.54  | 9.75 |    | FLR                         |
| 33 | 429.47  | 5.52 |    | GTPGV                       |



# Protein X - fragment

Digest Table


| #  | Pos     | Mass  | pl | Peptide                      |
|----|---------|-------|----|------------------------------|
| 1  | 1213.50 | 9.50  |    | MAAVAALQLGLR                 |
| 2  | 543.62  | 9.79  |    | AAGLGR                       |
| 3  | 828.93  | 9.79  |    | APASAAWR                     |
| 4  | 473.57  | 9.47  |    | SVLR                         |
| 5  | 1464.69 | 12.30 |    | VSPRPGVAWRPSR                |
| 6  | 1082.15 | 5.99  |    | CGSSAAEASATK                 |
| 7  | 3203.69 | 4.03  |    | AEDDSFLQWVLLIIPVTAFGLGTWQVQR |
| 8  | 174.20  | 9.75  |    | R                            |
| 9  | 146.19  | 8.75  |    | K                            |
| 10 | 332.40  | 8.75  |    | WK                           |
| 11 | 1157.33 | 4.53  |    | LNLIAELESR                   |
| 12 | 1719.07 | 4.14  |    | VLAEPVPLPADPMELK             |
| 13 | 1018.18 | 8.59  |    | NLEYRPVK                     |
| 14 | 273.34  | 9.72  |    | VR                           |
| 15 | 792.86  | 6.73  |    | GCFDHSK                      |
| 16 | 939.16  | 6.10  |    | ELYMMPR                      |

Digest Table


| #  | Pos | Mass    | pl   | Peptide                     |
|----|-----|---------|------|-----------------------------|
| 17 |     | 816.97  | 5.50 | TMVDPVR                     |
| 18 |     | 374.40  | 6.10 | EAR                         |
| 19 |     | 2654.93 | 5.32 | EGGLISSSTQSGAYVVTPFHCTDLGK  |
| 20 |     | 146.19  | 8.75 | K                           |
| 21 |     | 714.78  | 5.97 | VNPETR                      |
| 22 |     | 274.32  | 8.75 | QK                          |
| 23 |     | 1515.74 | 4.14 | GQIEGEVDLIGMVR              |
| 24 |     | 618.69  | 6.00 | LTETR                       |
| 25 |     | 1326.43 | 4.53 | QPFPENNPER                  |
| 26 |     | 911.98  | 8.76 | NHWHYR                      |
| 27 |     | 804.92  | 4.37 | DLEAMAR                     |
| 28 |     | 2744.06 | 4.37 | ITGAEPIFIDANFQSTVPGGPIGGQTR |
| 29 |     | 487.60  | 9.72 | VTLR                        |
| 30 |     | 2791.16 | 6.75 | NEHLQYIVTWYGLSAATSYLWFK     |
| 31 |     | 146.19  | 8.75 | K                           |
| 32 |     | 434.54  | 9.75 | FLR                         |
| 33 |     | 429.47  | 5.52 | GTPGV                       |



# Peptide selection - “good spectrum”



- Excellent sequence coverage
- High dispersion of energy
- Good for peptide ID




- Good sequence coverage
- Low dispersion of energy
- Good for quantitation



# Assay development outline





- Mass spectrometry (MS)
- Liquid chromatography (LC)
- LC-MS/MS method optimization and characterization
- Sample preparation





# Method development - mass spectrometry



- Acquisition of MS and MS/MS spectra for standard solution of the peptide
  - 10-50 $\mu$ M,
  - direct infusion
- Precursor ion – fragment ion MS parameters optimization
  - most efficient ionization; precursor ion preferably +2
  - most efficient fragmentation; fragment ions preferably with m/z higher than precursor ion
- Method set up and test run
  - Choose three precursor ion – fragment ion pairs for each peptide





# Liquid chromatography

- HPLC column
  - RP type column – C18
  - Retention
  - Separation – usually no need to have a base peak separation
  - Gradient elution
  - MS compatible solvents and buffer modifiers (0.1% FA in water, 0.1% FA in acetonitrile)
  - Shortest runs possible (usually 4-8 min per injection)






•

•

•

# LC-MS method optimization & characterization




- Linear calibration curve
- Limit of detection (LOD)
  - 3:1 signal-to-noise ratio
- Limit of quantitation (LOQ)
  - 10:1 signal-to-noise ratio
- Sample matrix interferences
  - analysis of blank sample matrix spiked with pure standard
- Carryover
- Stability of the analyte





# Sample preparation

- Objectives:
  - Isolating analyte from matrix
  - Removing contaminants, desalting
  - Concentrating analyte if necessary
  - Reconstituting in appropriate LC-MS compatible reagent
- Extraction methods:
  - Prior to proteolytic digest
    - Protein precipitation
      - Methanol
      - Acetonitrile
    - Immunoprecipitation
  - After proteolytic digest
    - Solid Phase Extraction (SPE)
      - C18
      - Ion exchange (e.g. SCX)
  - Combination of the above






# Quantitative LC-MS/MS assay

Each set of analyzed samples contains the following:

- 6-8 point calibration curve sets (in triplicate).  
A calibration curve set is usually run at the beginning, at the end, and once or more during the sample set.
- 1 QC per 10 samples (in triplicate)
- n# of samples (in triplicate)
- blank injections if necessary






# Results - QuanLynx report

Analyte and IS area

Signal-to-noise ratio

Calibration curve






# Most common challenges

- Internal standard (IS)
- Matrix effects
- Method validation



# Internal standard - to use or not to use?

- Benefit of IS:
  - If the analyte and IS suffer the same losses and the same effects in the matrix, matrix effects and sample losses cancel when we take the ratio of IS to analyte
- IS compensates for common analyte losses:
  - **Analyte adsorption on surfaces**
  - Extensive sample manipulation
  - Degradation
  - Evaporation
  - Autosampler variability






# Peptide adsorption on the surface


No IS

Compound name  
Correlation coefficient:  $r = 0.973449$ ,  $r^2 = 0.947603$   
Calibration curve:  $746.428 * x + -726.173$   
Response type: External Std, Area  
Curve type: Linear, Origin: Exclude, Weighting:  $1/x$ , Axis trans: None



With IS

Compound name  
Correlation coefficient:  $r = 0.994609$ ,  $r^2 = 0.989247$   
Calibration curve:  $6.64019 * x + -1.62103$   
Response type: Internal Std ( Ref 10 ), Area \* ( IS Conc. / IS Area )  
Curve type: Linear, Origin: Exclude, Weighting:  $1/x$ , Axis trans: None





# Extreme example


Compound name

Correlation coefficient:  $r = 0.852161$ ,  $r^2 = 0.726178$

Calibration curve:  $20.9105 * x + -1.15707$

Response type: Internal Std ( Ref 2 ), Area \* ( IS Conc. / IS Area )

Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis trans: None





# Tricks to improve calibration curve linearity

- Isotopically labeled internal standard
- Sample buffer modification:
  - Sample matrix
  - Diluted sample matrix
  - Addition of neutral protein
  - Higher organic solvent content



# Matrix effects

- Matrix effects:
  - Ion suppression
  - Interferences from metabolites
  - Signal enhancement
- Assessment of matrix effect:
  - Post-column infusion of analyte
  - Comparison of analyte in matrix-free solution vs. spiked blank matrix – extraction efficiency assessment
- Minimizing matrix effects:
  - Use isotopically labeled internal standard
  - Use fragment ions of  $m/z$  higher than precursor ion
  - Generate “cleaner” extract
  - Optimize HPLC method



# Method Validation


- Detection capability:
  - LOD – signal to noise ratio 3:1
  - LOQ – signal to noise ratio 10:1
- Calibration curve – linear dynamic range
- Precision and accuracy
- Selectivity
- Specificity
- Stability of analyte (and matrix):
  - Short-term, long-term
  - Low and high concentrations
  - Analyte in sample solvent and in raw matrix
  - Dry extract, reconstituted standard/extract
  - Freeze/thaw cycles



# Analyte stability


## With IS

Compound name  
Correlation coefficient:  $r = 0.999252$ ,  $r^2 = 0.998505$   
Calibration curve:  $0.440538 * x + 0.0156705$   
Response type: Internal Std ( Ref 2 ), Area \* ( IS Conc. / IS Area )  
Curve type: Linear, Origin: Exclude, Weighting:  $1/x$ , Axis trans: None



## No IS

Compound name  
Correlation coefficient:  $r = 0.970733$ ,  $r^2 = 0.942323$   
Calibration curve:  $4511.2 * x + 221.327$   
Response type: External Std, Area  
Curve type: Linear, Origin: Exclude, Weighting:  $1/x$ , Axis trans: None





# Literature References

1. Mass Spectrometry: Principles and Applications by Edmond de Hoffmann, Vincent Stroobant
2. Trace Quantitative Analysis by Mass Spectrometry by Robert K. Boyd, Cecilia Basic, Robert A. Bethem
3. LC/MS: A practical User's Guide by Marvin McMaster
4. Quantitative Proteomics by Mass Spectrometry by Salavatore Sechi
5. [www.ionsource.com](http://www.ionsource.com)
6. SUMS website: [mass-spec.stanford.edu](http://mass-spec.stanford.edu)



# Acknowledgements

Stanford University Mass Spectrometry Staff

- Allis Chien
- Chris Adams
- Pavel Aronov
- Theresa McLaughlin

Vincent and Stella Coates Foundation